Award
National Cancer Institute 5R01CA294640-02
Homologous recombination repair pathway mutations and genetic mechanisms shaping anti-tumor immunity and immunotherapy efficacy
Recipient
Cleveland Clinic Lerner College of Medicine (CLEVELAND CLINIC LERNER COM-CWRU)
Award Amount
$698,349.00
Ceiling
$698,349.00
Awarded
July 24, 2026
Identifier
5R01CA294640-02
Research project funded by the National Cancer Institute to study the impact of homologous recombination repair pathway mutations on tumor immunity and immunotherapy efficacy, focusing on mechanisms of immune response and resistance.
Description
This project investigates how mutations in homologous recombination (HR) DNA repair pathways influence tumor immunity and response to immunotherapy, particularly immune checkpoint blockade (ICB). The study aims to elucidate mechanisms underlying differential immunogenicity between BRCA1 and BRCA2 mutant tumors, characterize HR defect impacts on ICB response in human tumors, and explore mechanisms of acquired resistance post-therapy.